Phase 2 study of REOLYSIN (pelareorep) in combination with FOLFOX6, bevacizumab and pembrolizumab in female patients with KRAS-mutant colorectal cancer metastatic to the liver

Trial Profile

Phase 2 study of REOLYSIN (pelareorep) in combination with FOLFOX6, bevacizumab and pembrolizumab in female patients with KRAS-mutant colorectal cancer metastatic to the liver

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2016

At a glance

  • Drugs Pelareorep (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin; Pembrolizumab
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Jun 2016 According to an Oncolytics Biotech media release, the IND application to US FDA containing protocol for this trial is now active.
    • 29 Jun 2016 According to an Oncolytics Biotech media release, status changed from planning to not yet recruiting.
    • 25 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top